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ABSTRACT
Design: Qualitative interview study.
Participants: Fifty-nine patients with a family history of
cancer who attend a regional cancer genetics clinic in the
UK were interviewed about their current and previous
research experiences.
Findings: Interviewees gave a range of explanations for
research participation. These were categorised as (a)
social—research participation benefits the wider society
by progressing science and improving treatment for
everyone; (b) familial—research participation may
improve healthcare and benefit current or future genera-
tions of the participant’s family; and (c) personal—
research participation provides therapeutic or non-
therapeutic benefits for oneself.
Conclusions: We discuss the distinction drawn between
motives for research participation focused upon self
(personal) and others (familial/social), and observe that
personal, social and familial motives can be seen as
interdependent. For example, research participation that is
undertaken to benefit others, particularly relatives, may
also offer a number of personal benefits for self, such as
enabling participants to feel that they have discharged
their social or familial obligations. We argue for the need
to move away from simple, static, individualised notions
of research participation to a more complex, dynamic and
inherently social account.
The assumption that research participation is
motivated by altruism—helping others—rather
than undertaken for personal gain is widespread,1
particularly when it comes to research that
involves the donation of tissue2 or blood/DNA
samples:3 4
Altruism and trust lie at the heart of research on
human subjects. Altruistic individuals volunteer
for research because they trust that their partici-
pation will contribute to improved health for
others and that researchers will minimize risks to
participants. (p873)1
Although, as this recent consensus statement on
clinical trial demonstrates, this focus on altruism is
not confined to research involving human tissue
samples, it might be speculated that altruism may
feature to a greater extent in discussions of clinical
genetics-related research, primarily because this
research will, by definition, have a higher like-
lihood of benefiting a predefined group of people in
addition to the participants—their biological kin.
Looking more broadly, it has been observed that
the positioning of altruism as the primary moti-
vator of research participation in the UK may have
arisen as a result of public discussions about the
unconsented use of tissue/body parts in research2
and also in response to the seemingly exponential
growth in the number of initiatives to create
community-based DNA/tissue sample collections
(eg, UK Biobank, MRC sample collections) in
recent years.3 4 The scandal over retained organs
(and subsequent public inquiries) and the creation
of large-scale sample collections have resulted in
the development of legislation (in the UK, the
Human Tissue Act 2004) and a number of UK
guidelines5 6 for the regulation and oversight7 of
medical research involving human subjects/tissue
samples. As Busby notes,4 these characterise
research samples/donations as altruistic gifts, this
treatment being in line with the common law in
the UK.
Tutton3 argues that the current turn to altruism
to account for participation in biobanking projects
is influenced by Titmuss’s definitions of altruism,
which he developed in his comparative analysis of
blood donation in the UK and the USA.8 In this,
Titmuss conceptualises voluntary and unfettered
donations as ‘‘free human gifts’’, in which
[T]here are no tangible immediate rewards,
monetary or non-monetary: there are no penalties;
and donors know that their gifts are for unnamed
strangers without distinction of age, sex, medical
illness, income, class, religion or ethnic group.
(p385)
Titmuss does, however, problematise overly
simplistic notions of altruistic donation by point-
ing out that it involves both an awareness of need
and an expectation of reciprocity. According to
Titmuss,8 voluntary blood donation is a form of
reciprocal altruism; it is a gift that is accompanied
by the expectation that it will be reciprocated if,
and when, necessary. Titmuss does not see
reciprocal altruism as solely future-oriented, for
he cites research that suggests that some people
donate blood primarily to repay a donation that
has been received by someone they know.
Altruistic donation is thus characterised as a
cyclical, or recursive, process that repays past
donations and carries expectations of future
returns for oneself or one’s friends or family.
Thus, Titmuss acknowledges that altruistic dona-
tion may involve a degree of self-interest.
Titmuss’s analysis hints at the complexity of
individuals’ motives underlying voluntary blood
donation, and this is reinforced by the findings of
empirical studies of participation in genetics
research, which suggest that, although individuals
frequently describe their research participation as
motivated by altruism,9 10 they are also driven by
the anticipation of personal gain.11 Certainly, as far
as other types of clinical research are concerned
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there may be a number of obvious tangible benefits for research
participants.12 For example, there is a high probability that at
least a proportion of participants will get clinical benefit from
taking part in research that compares new with established
therapies and this is often identified as one motive for
participation in randomised clinical trials.13 Non-therapeutic
research (such as (genetic) epidemiological or psychological
research) may nevertheless have indirect or incidental clinical
benefits, for there is a possibility that participants may obtain a
result that has diagnostic consequences.14 Furthermore,
although many research projects (eg, social science or epide-
miological studies) may not appear to carry any clinical benefits
for research participants, this does not mean that participation
in research of this type is devoid of benefit per se, because the
act of participation itself may either generate positive feelings
about oneself or an enhanced self-image. Indeed, a recent study
suggests that many participants were very positive about calling
research donations ‘‘gifts’’, arguing that naming this activity in
this way made them feel good about themselves.2 In other
words, in addition to the clinical (and, in some cases, economic)
benefits that are associated with some types of research
participation, there may be internalised, self-regarding or
emotional rewards.
While research may directly or indirectly benefit participants,
this should not detract from the fact that many individuals say
they are motivated by altruism and take part in research
primarily to help others. For example, in their study of
participation in genetic testing research protocols, Geller and
colleagues observed that nearly 40% of participants stated that
they became involved to help researchers rather than for any
personal benefit, that is, to obtain a DNA test for themselves.9 A
recent Australasian study of the genetics of endometriosis
similarly reports that participants describe themselves as
motivated by a desire to contribute to scientific knowledge
and raise community awareness about the disease rather than
personal gain.10 Indeed, the idea that research participation may
benefit the wider community is frequently cited as a reason for
participation in genetic epidemiological research. Haimes and
Whong-Barr15 and Hoeyer16 describe how donors to population
biobanks in Cumbria (north-western England) and northern
Sweden described their decision to contribute tissue samples as
influenced by the desire to help research and to benefit society
and future patients, including family members. However, these
expressions of altruism were frequently qualified by intervie-
wees, who commented that their willingness to participate had
been influenced by the fact that the samples they donated
would normally be destroyed (umbilical cord blood and tissue
samples) or were interpreted as routine procedures (blood
samples)15 or perceived as of ‘‘no consequence’’.16 In other
words, interviewees were willing to participate in these projects,
at least in part, because they were not required to do much in
order to do so.
The idea that research participation may be influenced by
perceptions of the effort involved is discussed by Haimes and
Whong-Barr,15 who describe ‘‘different levels of participation’’ in
the Cumbrian study. They note that while a large proportion of
those approached were happy to donate tissue samples and thus
take part, at least in a partial way, a much smaller percentage
could be regarded as full participants—that is, they donated
tissue samples and completed questionnaires containing perso-
nal information about their health and lifestyle. They contend
that these different levels of participation map onto ‘‘styles of
participation’’, a more generalisable scheme that incorporates
underlying motives and includes: active participants, who are
keen to contribute, cost–benefit participants, who weigh up the
costs to self versus benefits to others, passive participants, who
participate because participation does not involve much in the
way of perceived risks or effort and, finally, reluctant participants,
who are persuaded to take part by researchers/others.15
THE NATURE OF ALTRUISM?
The foregoing discussion highlights the fact that research is not
a homogeneous activity, but involves different procedures and
risks and, as a consequence, very different participatory
experiences. Indeed, even within the broad categories of
therapeutic and non-therapeutic research there are important
differences between studies, involving greater or lesser risks and
benefits and more or less effort from participants. For example,
some research projects may involve daily or invasive and risky
procedures (randomised drug trials), whereas others may entail
a one-off donation of blood or non-invasive annual screening
tests (genetic epidemiological research or screening research).
These observations suggest that individuals may draw upon
notions of altruism (or personal benefit) to different degrees and
in different ways when accounting for their decision to take
part in different types of research. It can be speculated that
individuals may be more willing to be ‘‘altruistic’’ when (a) they
personally have little to lose from research participation15
because it involves little effort15–17 or few risks (eg, anonymised
epidemiological research) or there are no therapeutic options
available to them even though the effort required and risks may
be high (eg, non-therapeutic phase I trials) or (b) when the
benefits of participation for self and others are closely allied
despite the (increased) risks and/or effort (eg, therapeutic or
molecular genetics research). In an effort to explore some of
these issues, we undertook a series of semi-structured interviews
with patients who had been involved in therapeutic and/or non-
therapeutic research projects in a cancer genetics clinic in the
south of England.
The overall aim of this qualitative interview study was to
investigate lay and professional perceptions of the activities that
take place in the cancer genetics clinic.18 In addition to
healthcare professionals, researchers and other stakeholders,
the study included three groups of patients who had been
involved in different types of research projects. This paper looks
at the ways in which these patients framed their motivations
for research participation and argues that we need to move
away from simple, static, individualised notions of research
participation to a more complex, dynamic and inherently social
account.
THE RESEARCH SETTING
Cancer genetics is a highly research-active subspecialty; many
clinics in the UK were set up in the early 1990s to ascertain
patients for molecular genetics studies, and this research legacy
lives on today. Southampton (a regional genetics service
covering a population of 3 million) was an ideal site to base
our study, as it is one of the more active research centres in the
UK, hosting a number of local, national and international
research projects. For the purpose of our study these were
classified as clinical, molecular, epidemiological, psychosocial
and research registers.
Clinical research
This research involves studies that have a potential therapeutic
benefit for participants, including (a) screening or surveillance
studies, such as UKFOCSS (UK Familial Ovarian Cancer
Research ethics
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Screening Study), an observational study of blood serum testing
plus an annual transvaginal ultrasound; and MARIBS (Magnetic
Resonance Imaging for Breast Screening), involving annual MRI
or mammograms plus a blood sample at the end of the project
and questionnaires before and after each screen; and (b)
chemoprevention drug trials, such as CAPP2 (Colorectal
Adenoma/carcinoma Prevention Programme), using aspirin
and digestion-resistant starch, IBIS1 (International Breast
Cancer Intervention Study), using tamoxifen; or RAZOR
(Raloxifene and Zoladex Research Study), all of which involve
taking drugs or placebo in addition to dietary interventions
(CAPP2) and bodily surveillance (CAPP2, IBIS1, RAZOR).
Molecular or DNA-based research
This research may provide a diagnostic genetic test result, as in
the Familial Breast Cancer Study (the ‘‘BRCA3’’ study) (in
which BRCA1 and BRCA2mutation testing was undertaken—in
the early stages, before such testing was widely available as a
clinical service) or searching for mutations in rare cancer
syndromes (eg, Gorlin and Peutz-Jeghers syndromes).
Epidemiological studies
These comprise non-therapeutic research that requires few, if
any, physical interventions or procedures and include, for
example, EMBRACE (Epidemiological Study of Familial Breast
Cancer), involving questionnaires and a blood sample, and
POSH (Prospective Study of Outcomes in Sporadic Versus
Hereditary Breast Cancer ), an observational study of treatment
choices and outcomes of young breast cancer patients.
Psychosocial studies
These comprise non-therapeutic research such as qualitative
interview studies (eg, the psychological impact of VHL),
questionnaires or quality-of-life evaluations.
Research databases
These were set up as a resource for epidemiological studies, and
thus membership indicates a willingness to take part in future
research projects (British Familial Cancer Record and/or the UK
Coordinating Committee for Cancer Research’s Familial
Ovarian Cancer Register).
Focusing our research in this particular clinic, therefore,
offered us the ideal opportunity to consider and reflect upon
individuals’ accounts of their research participation in a wide
range of research studies. Moreover, recruiting our sample
from a single clinic facilitated the data collection and also
enabled us to keep population and other variables constant in
our sample.
METHODS
Recruitment
Ethics approval was obtained from Scotland’s Multi Research
Ethics Committee A in November 2005. Potential participants
who had attended the Wessex regional genetics service during
the previous 12 years to discuss their personal or family history
of cancer were approached with an invitation to participate.
Patients were purposively sampled from clinic lists and the
British Familial Cancer Record to include roughly equal groups
of interviewees who had previously participated in molecular
DNA-based research, clinical research, and epidemiological and
psychosocial research (table 1).
Data collection and analysis
In-depth face-to-face interviews were carried out by SC and GC
from March 2006 to March 2007 at a location of the
participant’s choice (home, workplace or genetics clinic).
These lasted for 40 to 90 minutes and were tape-recorded, with
consent. Interviews began with a number of demographic
questions and then interviewees were asked to provide a narrative
account of their involvement with the genetics clinic and research
projects they had previously participated in. Discussion about a
range of clinical and research activities was subsequently
prompted and interviewees’ responses were explored to establish:
their motivations for research participation and individuals’
motivations in general, their perceptions of clinic activities, the
differences and similarities between research and clinical practice
and their views about the ethical conduct of research.
One interview was conducted with two related participants,
so only 58 interviews were carried out. Transcripts were read
through many times by different team members to identify
recurrent themes within and between participants’ accounts.
The method of constant comparison19 was used to develop a
coding frame. The codes emerging from the analysis were
discussed and verified by members of the research team. Data
were managed using QSR N6.
RESULTS
Participants
One hundred and forty-four patients with a high risk of cancer
were sent an invitation pack containing an information sheet and
an expression-of-interest form to be returned to the research
team. Fifty-nine (41%)—12 men and 47 women—agreed to be
interviewed. The 59 interviewees were aged between 29 and 83
years (mean 50 years). Fifty (85%) of the interviewees had
children, and 34 of these (68%) had male and 44 (88%) female
children. Twenty-one interviewees (36%) for whom data are
available had further or higher educational qualifications.
Thirty-seven (63%) of the interviewees had previously had
cancer and 42 (71%) had undergone DNA testing. Thirty-five
(59%) had a family history of breast or ovarian cancer, 9 (15%)
bowel or colon cancer and 15 (25%) other types of cancer or
cancer syndromes.
According to their clinical notes, the interviewees had
participated in 1 to 6 research studies (mode 3) (see table 1),
including this one. Of the 52 interviewees who had previously
participated in research, one was recruited to a molecular
genetics study in 1984 and the remainder had been recruited
between 1995 and 2006. Forty-seven interviewees had partici-
pated in studies involving interventions that had potential
therapeutic benefits, including 22 who had taken part in
screening or chemoprevention studies (hereafter referred to as
‘‘CR’’) and 25 in molecular and DNA-based research (‘‘DNA’’),
29 had taken part in non-therapeutic epidemiological (‘‘EPI’’) or
psychosocial studies (‘‘PS’’) and 31 interviewees were members
of research databases (‘‘REG’’).
Accounting for research participation
Analysis revealed that our interviewees framed their previous, or
hypothetical, motivations for research participation in three
ways—personal, social and familial—and that these framings were
frequently juxtaposed within the interviews, so that, in practice, it
was difficult to characterise interviewees’ accounts as either self- or
other-oriented. However, although, the motives underlying
research participation coexist within interviewees’ accounts, they
will be presented separately for the purpose of analysis.
Research ethics
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But before we proceed, we need to comment upon the
homogeneity of the data, which was such that the views
expressed by our interviewees did not appear to be influenced
by age, gender, education or any of the other personal variables
described above, nor were they influenced in any obvious or
systematic way by previous experiences of, or the time elapsed
since, research participation. In what follows, interviewees are
referred to using their study number.
Accounting for participation: personal framing
P124: I think my own attitude towards research for me is purely
selfish. It’s what I feel I can get out of it, as much as anything … I
think people will take part in research if it affects them
personally. Because I think they feel being part of research they
feel they will probably get better clinical care. (EPI 2 years, REG 2
years)i
The majority of interviewees, like P124, offered personally
motivated reasons for their research participation at some point
in their interview. Many of those who had been involved in
clinical and DNA research said that they had participated in
order to obtain a diagnosis, treatment or surveillance. For
example, P149 explained that her participation in the MARIBS
study was motivated by the thought that she could access a
more accurate screening method (MRI) that might detect
cancers earlier than x ray mammography:
P149: [I]f there had been anything found I’m pretty sure I would
have been given the results. And that’s what I was led to believe
anyway. That’s how I felt about it. So you could say it wasn’t for
purely unselfish reasons to take part in that screening, because it
meant that anything that I had might have been picked up early
as a result of it. (DNA 8 years, REG 4 years, CR 6 years)
Many interviewees associated research participation with
receiving a higher standard of care, and some observed that
research was often marketed in this way, with information
focusing upon the potential benefits of participation rather than
the risks. For example, P142 described how she, and other
members of her family, had actually been ‘‘encouraged’’ to take
part in an observational ovarian screening study for high-risk
women (UKFOCSS) by the promise of therapeutic benefits:
P142: [T]he letters that came out indicated that ultrasound and
CA125 were quite positive ways to check for ovarian cancer and
although all the families were told it was a study, we were told
that there was a benefit to us, that there was not a certainty but
a good likelihood that if we were unlucky enough to develop
ovarian cancer, there was a very good chance of it being picked up
early because we were actually on the research study. (CR 4 and 6
years, REG 4 and 7 years, EPI 4 years)
Despite expressing some scepticism about the ways in which
UKFOCSS had initially been presented, she went on to describe
how her research participation had been clinically beneficial
because the research screening had identified some gynaecolo-
gical problems that would have not been diagnosed as quickly if
she had not been screened in the study.
While many interviewees admitted to participating in
research to gain direct clinical benefits, for some, the benefits,
although perceived as therapeutic, were not necessarily clinical.
For example, P115 explained that one of her reasons for
participating in the present study was that it gave her the
opportunity to talk about her cancer to a neutral third party:
Interviewer: Would that be one of the reasons you’d enter
research, because you felt you’d be getting better treatment?
P115: No. I’ve just entered it because I thought it would be a
chance to voice my opinions and speak to someone. And it’s like I
said, you can’t really talk, even to friends and family. (PS 0 years)
Likewise, P151 acknowledged that in addition to the potential
physical benefits of accessing tamoxifen, her participation in the
IBIS trial also had some psychological benefits, as it made her
feel as if she were proactively managing her risks of cancer:
P151: It was a mental benefit because you think, oh yes, I’m
actually not sitting back and thinking, oh dear, you know, this is
terrible. I’m trying to do something about it. (CR 9 years, DNA 5
years, REG 2 years)
These data suggest that when deciding to participate in
research, individuals attend to the nature of the research
procedures themselves and weigh up their associated benefits
to see what, if anything, they might gain from participation.
Thus, as many noted, participation is at least partially
motivated by ‘‘selfish’’ (P124, P149) reasons. The idea that
research participation is fuelled, at least in part, by the impact of
the research upon themselves is also reflected in the ways
interviewees accounted for their (potential) refusal of research
invitations. A number of interviewees claimed they were risk
averse and said that while they might take part in molecular,
psychosocial, epidemiological and even some types of some
clinical research, they would be unlikely to take part in clinical
Table 1 Previous research participation of interviewees
Type of research study Number
Therapeutic research
Molecular or DNA research 25
Familial Breast Cancer Study 11
Molecular research for rare diseases 9
Other (BRCA1 and 2) 5
Chemoprevention trial 9
CAPP2 6
RAZOR 1
IBIS1 2
Screening study 17
MARIBS 7
UKFOCCS 8
Other 2
Non-therapeutic research
Epidemiological 18
POSH 2
EMBRACE 12
Other 4
Psychosocial 11
Genetic counselling study 4
Von Hippel–Lindau interview study 4
Other 3
Research database 31
BFCR 29
UKCCCR Familial Ovarian Register 2
BFCR, British Familial Cancer Record; CAPP2, Colorectal Adenoma/Carcinoma
Prevention Programme; EMBRACE, Epidemiological Study of BRCA1 and BRCA2
Mutation Carriers; IBIS1, International Breast Cancer Intervention Study; MARIBS,
Magnetic Resonance Imaging for Breast Screening; POSH, Prospective Study of
Outcomes in Sporadic Versus Hereditary Breast Cancer; RAZOR, Raloxifene and
Zoladex Research Study; UKCCCR, UK Coordinating Committee on Cancer Research;
UKFOCSS, UK Familial Ovarian Cancer Screening Study.
i The types of research that interviewees had participated in and the time elapsed
since recruitment to different research projects are indicated after each quote.
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drug trials because they did not want to expose themselves to
the risks associated with ingesting unknown or untested
substances:
P148: I wouldn’t want to have to take drugs, really. I’m lucky in
that I don’t have to, which is, it’s naughty really because
somebody’s got to try these things, haven’t they! … I think, if I
hadn’t had the mastectomies and there was a chance of still
getting it, maybe I would think about doing a trial. But because,
hopefully, it’s gone I don’t know if I’d want to be a guinea pig for
new drugs. (DNA 8 years, REG 4 years, EPI 4 and 7 years)
While many commented that they should be prepared to run
these risks and be ‘‘a guinea pig’’ (P117: PS 2 and 3 years),
because, as P148 commented, ‘‘somebody’s got to try these
things’’, they also said they would only be prepared to be that
altruistic ‘‘somebody’’ if there was no further hope for
themselves or they had exhausted the available treatment
options:
P146: I don’t want to mess around with my body anymore now,
but if it [cancer] came back then I would be quite happy to take
part in a drugs trial if it meant a possible cure. (DNA 1 and 9
years, REG 5 years, EPI 7 years)
It would appear that even the most risk averse of our
interviewees would be prepared to run the risks associated with
research if they had nothing to lose—that is, if there were no
other treatment options on offer and/or the research offered
them the opportunity of personal benefits. However, while
some interviewees said that they had participated in research for
purely ‘‘selfish’’ (P124) or ‘‘not unselfish’’ (P149) reasons, to gain
some therapeutic benefit, and others would refuse to participate
in risky research, this does not mean that our interviewees were
not motivated to help others. As the next section shows, their
accounts were also peppered with altruistic explanations for
current, future and past research participation.
Accounting for participation: social framing
P148: I don’t think it’s [research participation] helped me any at
all because I haven’t really needed anything done … so, I’ve just
always looked on it as it’s research for somebody. I haven’t
thought of it as specifically helping me, because I’m not under
any doctors or anything. So, I just feel I don’t really medically, I
don’t really need any help, so I’m just quite happy to do this
research programme and that’s it really. (DNA 8 years, REG 4
years, EPI 4 and 6 years)
When reflecting upon their motivations for their research
participation a number of interviewees, like P148, said that
they had taken part with the intention of helping unspecified
others, or society more generally. However, very few con-
structed participation as purely motivated by the promise of
future gains for unknown others, for it was more frequently
framed as a form of exchange in which the potential or actual
benefits for themselves and others were counterbalanced. In
some cases research participation was described as motivated by
what Canvin and Jacoby call ‘‘weak altruism’’, namely,
instances in which individuals are ‘‘happy to help others but
only where they could also help themselves’’.17 As P123 notes,
although he had ‘‘selfish’’ motives for his participation in an
epidemiological study, he also recognised that it might benefit
others:
P123: I filled in the forms, because to my mind, if it didn’t help
me, it’s going to help somebody else, isn’t it? … it might be
selfish, but in a way, if they are testing my blood, they are
finding out if I’ve got anything in it, and they are helping me as
well as other people. If my tests help other people, well, that’s
good, because it’s not only helping them, it’s helping me as well.
So it’s twofold isn’t it? Yes, you’re getting back what you’re
putting in, really. (REG 1 year, EPI 7 years)
Others constructed their research participation as inspired by
a form of reciprocal altruism:8
P134: I think it was because you just feel so lucky that you’ve had
all this, the benefits of what’s been offered you, and you sort of
kind of think, well, if this is going to help, then it’s sort of a little
bit of—you’re giving a little bit back. (CR 3 years)
Likewise, P130, who had been on the CAPP2 trial for a
number of years, said that he had been partially motivated by a
desire to repay the clinic staff for the help he had received:
P130: [Y]ou wanted to help in some way because, they helped
me. You know, if it hadn’t been for the help I’d got, I
wouldn’t be sat here and you wouldn’t be sat there. So I
don’t think I felt obligated, I wanted to do it! And I was
happy to do it. Apart from the [daily intervention] I was
happy to continue doing it and we just kept on and on and
on. (CR 7 years)
Research participation was seen as a way of paying back the
clinical community, for their clinical care—care that, some
acknowledged, was only available now because of the altruistic
gestures of former participants. As P126b (CR 4 years, EPI 0, 3
and 4 years, PS 9 and 8 years) said, ‘‘If it wasn’t for people that
donated bits and pieces or whatever …’’. Similarly, P103 (CR 4
and 5 years) said that she felt she had a duty to participate in
research because ‘‘I’ve been very lucky, and a lot of that has
been down to trials and genetics and all that sort of thing. So I
just feel that if you can help, you should.’’
Research participation was seen as involving donation: the
giving of time, information, blood, tissue or one’s body. As P149
said about her participation in this study, ‘‘because anything
anybody can say to help, although I don’t think I’ve got
anything to say that would help. But what’s an hour of my
time?’’ For some, taking part in research involved a small
amount of time (P149) or a one-off blood donation and was seen
as not requiring too much effort:15–17
P126: So that was how I became involved and then she asked me
for a blood test which we didn’t really know what it was for at
the time. But blood tests don’t bother me so, and since then I
have entered anything they have asked because I firmly believe
that everything that I can do maybe will help my granddaughters
because their chance is 50/50 like us. (DNA 11 years, CR 2 years,
REG 4 years, EPI 3 and 4 years)
While many were prepared to participate if participation was
effortless and risk-free, some, like P109, acknowledged that such
considerations were not entirely altruistic and could be
interpreted as ‘‘selfish’’ motivations:
P109: [I]t’s not something I feel pressurised about because I don’t
feel I have to get it right or wrong, because it’s not going to
actually have that much bearing on me personally, which
probably sounds a bit selfish, but, if you know what I mean,
there’s no pressure on me if I don’t answer your questions right,
… I’ve got the time and I feel fine then fine, I’ll do it. If I haven’t,
if I was your average Joe that worked nine-to-five and blah-blah-
blah, I’d say ‘‘I wouldn’t be putting myself out.’’ (PS 2 and 3
years)
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Others experienced their participation as more onerous. For
example, P144 (CR 3 years, REG 3 years), a UKFOCSS
participant, did not resent the ongoing commitment or the
time involved, but regarded going for blood serum testing three
times a year as a ‘‘real pain’’. However, the economic (P142) or
other sacrifices (P130, P144) that interviewees had made were
frequently justified by the returns:
P142: At times it’s [research participation] been a little bit tedious
you know the travelling back and forwards and the cost but over
all I think it’s an important thing to do and as I say all knowledge
is good and the more work is done over the whole world the
more information can be done about people who suffer from
these types of cancers. (CR 4 and 6 years, REG 4 and 7 years, EPI 4
years)
Like P142, many interviewees observed that they were willing
to make these donations because they believed that research
was necessary to progress our understanding of genetics or
cancer. In relation to this, many commented that they had a
duty to participate to help bring about scientific advances so
that future generations of society would have access to
improved treatment. As P114 (PS 2 and 3 years) said about
research participation, ‘‘It’s got to be done, it’s got to be done,
really. I’m taking a long-term view. We want to get this right
for the next generation, don’t we?’’ Research participation was
thus framed as a way of behaving as a responsible citizen,20 as
enabling one to fulfil social obligations to future persons:
P147: I do feel like it’s part of the jigsaw puzzle and I’m part of
that and it’s important and I have a responsibility. Now I’ve got
the faulty gene I don’t just feel for myself I feel this is about
others in the future and I do feel quite responsible about that.
(CR 5 years, REG 3 years, EPI 7 years)
Indeed, some interviewees observed that the advancement of
science and development of future treatment or services was so
important that one should be prepared to take risks that
otherwise might be rejected:
P128: But I am happy to go along with the element of risk. You
can’t advance technology or chemistry, human chemistry with-
out an element of risk anyway, can you? (CR 6 years, REG 2
years)
But those who were prepared to expose themselves to
disproportionate risks or inconvenience for the greater good,
like P128, were in the minority, for, as noted earlier, there was
some indication that interviewees’ motivations to participate in
research were tempered by their perceptions of the risk–benefit
ratio.
In summary, all the interviewees said they were prepared to
take part in research that offered them no (direct or obvious)
personal benefits and went on to describe some of the
conditions for altruistic research participation. These included:
the nature of the risks, the availability of clinical care, their
health status and finally, as we will see, who in particular might
benefit from their research participation.
Accounting for participation: familial framing
Even though most interviewees said that their research
participation was motivated by a desire to help others, these
expressions of altruism were frequently tempered by the
recognition that their participation might directly benefit those
they cared about, namely their biological kin:
P126: I have entered anything they have asked because I firmly
believe that everything that I can do maybe will help my
granddaughters because their chance is 50/50 like us … I want
my granddaughters to be alright. And every time you do it
[participate in research] it’s a step nearer perhaps isn’t it? And of
course you have got a terrible guilt … I have of giving it
[mutation] to … (DNA 11 years, CR 2 years, REG 4 years, EPI 3
and 4 years)
Thus, while many interviewees said that they were prepared
to behave in an altruistic manner and run risks for others’
benefit, most acknowledged that this was not always totally
selfless behaviour, because on many occasions these others were
significant others, people that they cared about or cared for—
their relatives:
P110:My personal motivations are my son. My son has VHL and
… I’d like him to grow up and there’d be some kind of cure for it,
so. But beyond that, it’s just a belief that there should be research
and um, if it’s possible to do, then do it. (PS 2 and 3 years)
Most interviewees said that they had been/were willing to
participate in research because it might directly help current
children, grandchildren or siblings or future family members.
P142:Obviously there is the positive scientific motivation that all
knowledge really is good knowledge. And it’s better to have
knowledge, then there is obviously the big positive for my
children, that if the research brings up ideas, or deductions or
new ways of clinically testing people before they have gone down
with cancer, you know it gives everybody in the future a better
opportunity. (CR 4 and 6 years, REG 4 and 7 years, EPI 4 years)
In this sense, research participation was not seen as
motivated by ‘‘pure’’ altruism, in the sense that it was perceived
as an ‘‘unfettered donation’’,8 because, as many interviewees
commented, it was undertaken with the expectation that it
might benefit those that they had an interest in protecting:
P104: I mean, it’s [research participation] sort of for selfish
reasons at the back of my mind, I’ve got two daughters so
anything that can be done to help the understanding of what’s
going on will help them in the long term, won’t it. (CR 5 years,
REG 5 years, EPI 4 years)
The idea that family interests are coterminous with one’s
own interests was expressed in many interviews:
Interviewer: And do you think, is there any particular types of
research that you wouldn’t consider taking part in if you were
asked?
P105: No, I don’t. If it could find a way of stopping this [cancer]
happening, then obviously—we’ve got a big family of girls, so if it
is something in our family, it would be great to find a way of
preventing it. So I’m game for anything … when it’s like in the
family like that, I think really it’s in your best interests to say yes,
right-ho, whatever. (CR 3 years)
Although research participation that helps others is normally
seen as motivated by altruism, in certain instances our
interviewees constructed this ‘‘altruistic’’ behaviour as ‘‘selfish’’
(eg, P104, P137). P131 reflected upon his varying motivations for
participation in CAPP2, acknowledging that a more selfish
agenda of helping his family exists alongside his more altruistic
motives of helping others with the disease more generally:
P131: Primarily because I felt that if I was helping other people,
and if there was likely to be something that—not necessarily a
cure, but something that would relieve the symptoms or the
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possibilities of bowel cancer in other people, then I thought I—
you know, I was fortunate enough to have survived it, and
fortunate enough to be in a position to take part and help other
people. But obviously, in a selfish way, my own children and my
grandchildren, if my own bloodline is likely or possibly—you
know? (CR 3 years)
It can be argued that participation in research that benefits
one’s family is constructed as selfish because it indirectly
benefits oneself, in so far as it allows one to fulfil one’s familial
obligations of care.21 For example, P137 said she would put her
self at risk by participating in more intrusive research, but only
if it enabled her to ‘‘save’’ or ‘‘help’’ those she cared for:
P137: If you said you wanted to test an anticancer drug on me
[laughter] or something, unfortunately I would be selfish here,
and it would have to be something that I could feel somebody
close, my daughter, or relatives could benefit if I said yes, that
could save, or that could help then I would do it but otherwise I
am afraid … (CR 6 and 8 years, REG 2 years)
In presenting themselves as someone who is ‘‘game for
anything’’ (P105) and who will do what they can, within limits,
to protect those they are related to, our participants were thus
able to construct themselves as responsible and caring individuals.
Framing research participation: a dynamic process
Although we have presented the motives for research participa-
tion separately in this analysis, even the most cursory reading of
these data demonstrates that these motivations coexist in
complex, interrelated ways within the interviews. As is
illustrated in P151’s account of her participation in the IBIS
trial, it is apparent that the various motivational framings for
participation stand in a dynamic relationship, in so far as they
impact upon each other and metamorphose in the telling:
P151: [I] would say I think it’s more for other people. But
specifically with the tamoxifen, I mean obviously if I hadn’t been
on tamoxifen, it [research participation] would have been of no
benefit to me at all.
Interviewer: Your decision to be involved in IBIS, what was behind
that?
P151: Well, once I knew about it, the first thought in my mind
was my daughter. I thought, ‘‘Right, if I can do something,
positive, rather than just sit round and do nothing.’’ And also of
course it was selfish as well, because I thought, ‘‘Well, I might get
to have some tamoxifen and the extra care’’ … So it was both
really, for me and for society in general. (CR 9 years, DNA 5 years,
REG 2 years)
Like P151, our interviewees typically said that they had taken,
or would take, part in research for many reasons, one of which
might be to gain personal therapeutic benefits—access to
treatment (personal direct gain)—at the same time this
participation may be acknowledged as adding to the sum of
knowledge about treatment that may benefit future generations
of patients (social direct gain), and the participant’s family
(direct familial gain), which, in turn, benefits oneself as it
enables one to fulfil one’s social obligations of citizenship and
one’s familial obligations of care (indirect personal gain). In
other words, the data suggest that the motives underlying
research participation are constructed as existing in an inter-
dependent relationship that can be represented as interleaved
and interlocking. Like the cogs depicted in fig 1, drawing upon
any one motive to account for one’s behaviour in this context is
not sufficient, for each motive would appear to impact upon,
alter and modify others in a recursive or dynamic fashion.
DISCUSSION
This study sought to determine research participants’ motivations
for takingpart in a rangeofdifferent typesof researchprojects in the
UK related to cancer genetics.Our interviewees framed themotives
underlying research participation in a variety of ways and talked
about the benefits for themselves, their families and the wider
society. Thus, on one level, our findings echo those reported in
earlier studies, which suggest that research participation is fuelled
byaltruistic aswell asmorepersonalmotives.11–13 22However, itwas
also noted that individuals’ motivations for research participation
are often difficult to describe as either self- or other-oriented, for the
different framings coexist in a number of complex and dynamic
ways within these interviews; indeed, the interviewees repeatedly
juxtaposed these different framings when discussing their former
and future research participation. The fact that our interviewees
reported different motives for research participation in these
interviewswithout any apparent tension or contradiction suggests
that the presentation of the motives underlying research participa-
tion as dichotomous, as reflecting the oppositional categories of self
versusother (seediscussionof literature in17) is a simplificationand
a methodological or analytical artifice.
Following Canvin and Jacoby17 and Haimes and Whong-
Barr,15 we speculated that the degree to which individuals might
draw on altruism to account for their (hypothetical) research
participation may be related to the risk–benefit ratio, the
amount of effort involved in particular projects and the
individual’s personal situation. This seems to have been borne
out by the data indicating that when citing altruism as a motive
our interviewees appeared to take into account a combination
of personal circumstances—primarily health status—and the
particular requirements of the research. In other words, our
interviewees regard altruism as context-dependent and con-
struct it as a particularised rather than a general concept.
Thus, although most of our interviewees claimed they would,
or indeed should, participate in research to help future patients
including their family, in the main they said that they were only
prepared to engage in these activities if this did not put their
health needlessly at risk,17 22 23 if they might also benefit or if
they had exhausted all therapeutic options. These findings
recapitulate those of an earlier study that found respondents
favour recruitment (without their consent) to hypothetical
research studies that involve experimental drugs that their
doctor thinks ‘‘might help them’’ rather than to placebo-based
randomised controlled trials and also rate the less invasive
Figure 1 Framing motives for research participation.
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interventions as more acceptable.24 Dixon-Woods and colleagues
similarly observed that while the parents in their study voiced
communitarian motives for research participation, they were
willing to donate their child’s tissue for research only if they
perceived there was no risk to their child.2 23 Our data similarly
imply that there are limits to research participants’ altruism—
things they will not do or risks they will not take to help
others—suggesting, as Haimes and Whong-Barr contend, that
the truly altruistic participant who will run any number of risks
and expend a large amount of effort purely for others’ benefit is,
indeed, very rare.15
The fact that our interviewees said they would be less likely to
participate in drug trials or invasive research implies that they
perceive the epidemiological, molecular and psychosocial research
that takes place in cancer genetics clinics as less risky.
Alternatively, they may be less aware of the psychosocial and
economic risks—the emotional sequelae and potential disruption
of family relationships that can be associated with these types of
research.11 14 Indeed, research with those who undergo clinical
genetic testing suggests they are often unaware of the emotional
sequelae and potential impact on family relationships.25 21
One of the problems with the above interpretation of the data
is that it constructs research participation, in general, and
altruism, in particular, as individualised behaviour and underplays
the fact that our interviewees are social actors who exist within a
network of social relations. Dixon-Woods and Tarrant23 have
recently argued that we need to see research as social action,
involving cooperation between researchers and participants. They
argue that cooperative research is a form of ‘‘joint action’’—a
dynamic form of collaborative social interaction, in which the
actions of both parties and the relationships that exist, or are
created, between them are fundamentally important.
Constructing research activities in this way has the effect of
redirecting our focus upon the relationships that exist between
the different parties—researchers and participants, participants
and their families and participants and the wider society.
Using data collected in three different studies, Dixon-Woods
and Tarrant23 observed that interviewees consistently emphasise
‘‘the moral character of research participation’’ acknowledging
that this activity contributes to the common good to which all
responsible people should contribute (see also Harris26). The idea
that researchers and participants are engaged in a cooperative
relationship was supported in this study by the observation that
many of our interviewees talked about their research participation
in terms of reciprocal altruism—as paying back former participants
for their participation in earlier studies or the clinical staff who
recruited or cared for them. This reiterates Titmuss’s observations
that blood donors often describe their donations as repayment for
past transfusions8 and also has been described by Dixon-Woods
and colleagues in their recent study of tissue donation.2
Many of our interviewees also talked about how they wanted
to contribute to discoveries in cancer/genetics research, again
suggesting that they regarded their research participation as a
cooperative venture, one of the aims of which is to contribute to
knowledge17 22 and the advancement of science or of treat-
ment,10 These data, therefore, demonstrate that our intervie-
wees were clearly aware of the epistemological basis of research
activities. Thus, while they may see their research participation
as motivated by a number of disparate motives, including a
desire to gain therapeutic benefits,13 the data suggest it is not
primarily sustained by a therapeutic misconception27 28 that is
characterised by Henderson and colleagues as a failure to
understand ‘‘that the defining purpose of clinical research is to
produce generalisable knowledge’’ (P4).29
Our data also indicate that our interviewees are well aware of
‘‘the moral character of research participation’’. Dixon-Woods
and Tarrant warn, however, that one should be wary of
interpreting accounts of research participation in this way,
pointing out that accounts that describe participation in
medical research as serving the public good are often, among
other things, ‘‘evidence of the more general attempt to defend
moral character found in most accounts of action’’ (p4).23 To
some extent we agree, and acknowledge that both the research
design and the subject matter of these interviews may have
encouraged our interviewees to present themselves as morally
accountable for their actions.15 However, we argue that we
should not just dismiss this type of account as a methodological
artifact. By describing the conflicting and often complex
motivations underlying their research participation, our inter-
viewees provided us with important insight into how morality
is negotiated and illuminated some of the complexities involved
in constructing oneself as a moral being in the context of what
is rapidly becoming a research culture.
To illustrate, nearly 20% of the interviewees referred to their
research participation as ‘‘selfish’’, either because it directly
benefited themselves, for example, provided access to treatment
(P151) and did not expose them to any form of risk (P109), or,
more frequently, because it provided some form of indirect
personal gain, for example, it might benefit their family (P123,
P104). Although we might expect that actions taken to benefit
oneself or to avoid exposure to risk would be described as
selfish, those that are undertaken to protect and benefit one’s
family or others, especially those involving a degree of burden or
risk, would normally be viewed as laudable and selfless
behaviour—as examples of altruism. Thus, it is interesting to
note that some of our interviewees regarded behaviour that
benefits others—family members—as motivated by a degree of
self-interest, suggesting that they see themselves as falling short
of some ideal model of participation— a model in which
research participation is seen as arising from some form of
unadulterated altruism. While the interviewees’ recourse to a
discourse of selfishness to account for their behaviour in these
instances could be read as some form of an apology, it could
equally be seen as evidence that altruism is more ethically
complex than even Titmuss has suggested.8
We speculated in our introduction that altruism may be
emphasised to a greater extent when participating in certain
types of genetics-related research. Previous research indicates
that family relationships play a major role in decision-making
about clinical genetic testing.21 25 There is evidence that many
men and women attend cancer genetic counselling and proceed
to DNA testing primarily to gain a diagnosis that family
members can use to obtain testing for themselves.25 21 While
such actions can clearly be described as altruistic, it has been
observed that they also benefit the individual by allowing them
to fulfil their familial obligations of care.25 21 It can be argued
that participation in genetics-related research, an activity that,
by definition, may (directly) benefit future generations of the
participants’ family, is seen in the same way. At one and the
same time, research participation is altruistic (one’s actions are
undertaken to benefit others) and can be seen as selfish (one’s
actions indirectly benefit oneself). Such observations suggest
that we may need to rethink the concept of altruism and what
Dixon-Woods and Tarrant23 refer to as the ‘‘moral character of
research participation’’. Also, as we noted earlier, we need to
recognise that when it comes to accounting for research
participation we can no longer regard altruism and selfishness
as incompatible or oppositional concepts. Indeed, it would
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appear that research participation is experienced as a more
ethically contentious activity than has heretofore been assumed.
LIMITATIONS
Finally, we need to consider the importance of personal experience
in these accounts. All our interviewees were at increased risk of
cancer, but healthy, when interviewed. However, the extent to
which their accounts were based on personal experiences varied:
some had taken part in a wide variety of projects, but others had
not and so could only speculate about what they might do in a
given situation. Thus, the data consist of two types of account:
general accounts, in which research participation is framed as a
hypothetical scenario, and more particularised accounts, con-
structed from real-life experiences. We would argue that
juxtaposing these in the above analysis is acceptable, not least
because both are underpinned by similar (ethical) reasoning, but
also because accounts based upon previous experiences, like
hypothetical accounts, are informed by the social context in
which they are produced. As noted above, as is the case in all
interview studies, our interviewees were subject to a moral
pressure to ‘‘perform’’ well in the interview and present self in a
favourable light. In this respect, accounts that purport to be based
upon personal experiences could be, better, interpreted as post hoc
rationalisations of behaviour30 rather than reports of ‘‘actual’’
motives underlying previous research participation. Similarly,
when engaging in speculation about how they might behave
when faced with research invitations in the future, it is possible
that many of our interviewees sought to present themselves as
responsible individuals.
CONCLUSIONS AND IMPLICATIONS
This study suggests that participation in research relating to
cancer genetics is seen as an activity that serves many disparate
purposes or interests and that benefits a range of people. Our
data indicate that research participation is influenced by the
hope of personal gain; by a desire to help researchers or future
patients and to repay former participants and clinical staff; and
by the wish to advance science and to help members of one’s
family or the wider society. It would appear that participants’
motives are less than straightforward and involve much more
than simply weighing up the risks and benefits to self or simply
balancing altruistic and selfish motivations. Indeed, it can be
argued that research participants see themselves as positioned
in a complex network of relationships in which their actions
are tied to others in the past and future. Thus, while the
process of consenting to participate in research projects in
cancer genetics can be viewed as an exercise of individual
agency—for, after all, it is the individual who signs the consent
form, allows blood to be drawn for DNA analysis, undergoes
MRI screening, takes trial medications or fills in a question-
naire—the motivations underlying such behaviour can be seen
as multi-faceted and complex and, according to these inter-
viewees, and as others have observed,29 are also profoundly
social in origin.
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